Quarterly report · Q1
3055.TEDINET S100OVJX
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥63.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥60.4bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥402m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥159m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥811m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥508m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥863m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥831m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥645m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥831m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥645m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥139.3bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥136.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥136.7bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥83.5bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥81.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥55.9bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥54.5bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥24.0bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥24.0bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥61m | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥332m | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥191m | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥159m | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥36.86 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.84 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.8% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥17m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥985m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥50m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥367m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥96m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥270m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥8m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥15.7bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥15.6bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥117m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥312m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥972m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥972m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥68m |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥46.2bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥43.8bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥178m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥67.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥63.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.5bn |
| Otherother segments | revenue | 2021-04-01 → 2021-06-30 | ¥770m |
| Otherother segments | revenue external | 2021-04-01 → 2021-06-30 | ¥16m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥754m |
| Otherother segments | segment profit | 2021-04-01 → 2021-06-30 | ¥422m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥3m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥14m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥324m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥94m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥229m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥18m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥14.9bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥14.7bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥132m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥240m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥936m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥932m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥4m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥50m |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥43.6bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥41.3bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥2.3bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥37m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥63.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥60.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥679m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1QuarterInstant | 22707000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 24017000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 41330000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 14722000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | 3328000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 932000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 94000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 16000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 60426000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 2311000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 132000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 4000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 229000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | 754000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3435000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 43641000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 14855000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | 3332000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 936000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 324000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 770000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 63862000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | -37000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 240000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | -14000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 50000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 18000000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | 422000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 679000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 43831000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 15612000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | 3326000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 972000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 96000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 17000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 63855000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 2369000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 117000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | 2000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 270000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | 1331000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 4092000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 46200000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 15729000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | 3329000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 972000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 367000000 | JPY |
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 1348000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |